|
|
 |
|
Viewing report
|
|
|
|
R&D Information Technology Markets for the U.S. Life Sciences Industry
Frost & Sullivan, Sep 2003
Niche Participants to Gain Partnership Opportunities from Large Companies
Smaller participants are in danger of being nudged out by larger vendors with deep pockets and service capabilities to survive extreme price fluctuations. Intent on acquiring key top-tier customers, larger multiverticals are pushing combined service and product solutions, often at market floor rates achieved through local subcontracting. Smaller companies are being forced to prove their long-term financial viability to be considered in the running. Nevertheless, niche participants are likely to attract the large companies that wish to penetrate smaller pockets such as the discovery IT business. Such collaborations will help the big participants form long-term relationships with their buyers.
This research examines the R&D Information Technology Markets for the U.S. Life Sciences Industry. It offers revenue forecasts by market segments and covers key drivers and restraints affecting market growth. It also provides strategic recommendations to overcome market challenges. It analyzes the growth of demand from workflow specific systems to architecture technologies like grid computing and next generation databases.
Large Vendors Can Cross-Leverage Technology to Maximize Profits
IT in life sciences starts with end-user applications. Established end-user application providers have built an entrenched core competency in the life sciences vertical, which has acted to create a strong inside affiliation among research chemists and other strong influencers over time.
The real interest in 2003 is coming from relatively industry neutral IT segments such as data storage, computing, and grid technology. Vendors from these segments can cost-effectively leverage their products into the life sciences market by aggressively pursuing partnership channels with these established end-user applications vendors.
Changing Business Models to Dictate the IT Market
The phasing out of blockbuster drugs is being expedited by drug manufacturers' struggle to increase their long-term pipelines. Newer strategies place the accent on a 'multibuster' approach to drug research, which discards a bottleneck-ridden 'single drug for all' method in favor of smaller, specialized drugs. This will have diverse benefits as the workflow and research process will expand manifold into compartmentalized research areas to produce specialized therapies in shorter periods, notes the analyst.
Although the multibuster approach is still only in the exploratory phase among most research organizations, it has enough merit to pass as a compelling business case. If this happens, workflow tools, data management, and laboratory information management systems vendors will gain most from it, remarks the analyst.
Customers who bought this item also bought
Singaporean Pharmaceuticals and Life Sciences IT Market
European Markets for Grid Computing in Life Sciences R&D
Bioinformatics Outsourcing for Life Sciences: India Opportunity
U.S. Electronic Lab Notebook Markets for Life Sciences
Emerging U.S. EDetailing Markets for Life Sciences
U.S. PLM Markets for Life Sciences
Strategic Analysis - U.S. Data Mining and Predictive Analytics Markets for Life Sciences R&D
Global Life Sciences Tools & Services
IT Software Tools for Life Science and Drug Discovery R&D
IT Software Tools for Life Science and Drug Discovery R&D
U.S. Computational Software Markets for Discovery Phase Research in Life Sciences
North American Analytical Instrumentation and Services Markets in Life Sciences
|
|
|
|
